Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.

Total
0
Shares
Related Posts
Read More

5 Value Stocks In The Energy Sector

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

EPSN